High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

Abstract Background MiT-Renal Cell Carcinoma (RCC) is characterized by genomic translocations involving microphthalmia-associated transcription factor (MiT) family members TFE3, TFEB, or MITF. MiT-RCC represents a specific subtype of sporadic RCC that is predominantly seen in young patients and can...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Martin Lang, Laura S. Schmidt, Kelli M. Wilson, Christopher J. Ricketts, Carole Sourbier, Cathy D. Vocke, Darmood Wei, Daniel R. Crooks, Youfeng Yang, Benjamin K. Gibbs, Xiaohu Zhang, Carleen Klumpp-Thomas, Lu Chen, Rajarshi Guha, Marc Ferrer, Crystal McKnight, Zina Itkin, Darawalee Wangsa, Danny Wangsa, Amy James, Simone Difilippantonio, Baktir Karim, Francisco Morís, Thomas Ried, Maria J. Merino, Ramaprasad Srinivasan, Craig J. Thomas, W. Marston Linehan
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: BMC 2023-04-01
Cyfres:Journal of Experimental & Clinical Cancer Research
Pynciau:
MiT family translocation RCC
TFE3-RCC
TFE3-fusion
GPNMB
RCC therapy
NVP-BGT226
Mynediad Ar-lein:https://doi.org/10.1186/s13046-023-02667-4

Rhyngrwyd

https://doi.org/10.1186/s13046-023-02667-4

Eitemau Tebyg